← All trials
NCT04878055
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 14, 2021
- Primary completion
- Sep 30, 2021
- Completion date
- Oct 31, 2021
- First posted
- May 7, 2021
- Last posted
- Sep 5, 2021
- Enrollment
- 312
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dompe PharmaceuticalsLead sponsor
- IRCCS Ospedale San Raffaele Centro di Ricerca Anestesia e RianimazioneOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.